IN THE CLAIMS:

Please amend the following claims:

- 3. (Amended) A steroid derivative according to claim 1 [or 2], wherein R_4 is an acyl group, in which hydrogen, or an alkoxy or alkyl group, is attached to the keto group.
- 4. (Amended) A steroid derivative according to [any one of the preceding claims] claim 1, wherein R₄ is acetyl (CH₃CO), wherein a keto group is attached to a methyl, which keto-carbon numbered 20 can have any alkyl, alkenyl, alkynyl, aryl, including branched side chains or mixed aromatic and aliphatic side chains, including cyclic saturated hydrocarbons as well as heterocyclic rings or heteroaliphatic chains containing e.g. N, P, O, Si, S, Se, CN, halogens and containing up to 20 carbons.
- 5. (Amended) A steroid derivative according to [any of the preceding claims] claim 1, wherein said steroid is selected from the group consisting of 5-androstene-3 β , 7 β , 17 α -triol, 5 androstene-3 β , 17 α -diol-7-one, androstane-3 β , 7 β , 17 α -triol and androstane-3 β , 17 α -diol-7-one, or an ester or ether thereof.
- 10. (Amended) Use according to claim 8 [or 9], wherein R_4 is an acyl group, in which hydrogen, or an alkoxy, alkyl, alkenyl or alkinyl group, is attached to the keto group.
- 12. (Amended) Use according to [any one of claim 7-11] claim 7, wherein said steroid is selected from the group consisting of 17-hydroxy-pregnenolone (17 α -OH), Δ -5-androstene-3 β , 17 α -diol, 5-androstene-3 β ,7 β ,17 α -triol, 5-androstene-3 β ,7 α ,17 α -triol, 5-androstene-3 β ,7 α ,17 α -triol, 5-androstene-3 β ,7 α ,17 α -triol, 5-androstene-3 β ,17 α -diol.
- 13. (Amended) Use according to [any one of claims 7-12] claim 7, wherein one or more pregnane- and/or androstane-derivative corresponding to the steroid is used in the manufacture of the medicament.
- 14. (Amended) Use according to [any one of claims 7-13] claim 7, wherein said interruption is

provided by downregulating an overexpression of cyclin D1 and β -catenin.

- 15. (Amended) Use according to [any one of claims 7-14] claim 7, wherein said effects are essentially independent of any direct apoptotic effect on the cells of said tumour.
- 16. (Amended) Use according to [any one of claims 7-15] claim 7, wherein said medicament is for the treatment and/or prevention of at least one medical condition selected from the group consisting of colon malignancies and other malignancies with a genotypic or phenotypic overexpression of factors belonging to the Wnt-signaling pathway, such as lung cancers, melanomas, breast cancers, mantle cell lymphomas and other lymphomas characterized by an upregulation of said factors, head and neck cancers of squamous cell origin, oesophagal cancers, parathyroid cancers or adenomas or other tumours characterized by a disturbance in Wnt-signaling; and conditions dominated by pathologic neovascularisation, such as diabetic retinopathy, exsudative forms of macular degeneration, corneal neovascularisation, and vascular tumours.
- 19. (Amended) A method according to claim 17 [or-18], wherein the medicament is for the treatment and/or prevention of a condition selected from the group consisting of urothelial cancers, gastric cancers, cancers of the smaller intestine, pancreatic cancers, tumours derived from endothelial cells, from smooth muscle cells, cancer of the colon, chorioncarcinomas, adenocarcinomas of the lung and liposarcomas, and pathology of the eye tissues, such as cells of the macula and glaucoma.
- 22. (Amended) A medicament produced according to [any one of claims 17-19] claim 17, which is suitable for the treatment and/or prevention of an inflammatory condition of the eye or in dry macular degeneration.
- 23. (Amended) A medicament produced according to [any one of claims 17-19] claim 17, where a prolongation of its effect is achieved through inhibition of sulphatase activity e.g. through simultaneous administration of an inhibitor such as Coumate®.

- 24. (Amended) A method according to [any one of claims 17-19] claim 17, where 5-androstene- 17α -ol- 3β -sulfate or androstane- 17α -ol- 3β -sulfate are produced synthetically.
- 25. (Amended) A pharmaceutical composition produced according to the method of [any one of elaims 17-19] claim 17 and further comprising 9-cis-retinoic acid, one or more corticosteroids or other ligands of nuclear receptors such as androgens, deltanoids, estrogens, retinoids, HNF-4, COUPTF, RXR, RAR, progestins, rexinoids, or cofactors of these or ligands to PPAR- α , δ , γ , having the same biological function in order to attenuate the effect.
- 27. (Amended) A method for the treatment of humans suffering from benign and malignant tumours, wherein a therapeutically active amount of a compound according to [elaims 1 to 6, and elaims 7-16] claim 1.